Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial

Abstract

Background: Proton pump inhibitors are effective for functional dyspepsia but ineffective in relieving postprandial distress syndrome. Curcuma longa might be effective for postprandial distress syndrome. The objective of this study was to compare the efficacy of Curcuma longa and simethicone for postprandial distress syndrome in an open-label randomized-controlled trial. Methods: This trial was conducted between July 2018 and February 2019. In total, 78 patients were randomly assigned to receive 4 weeks of treatment with 750 or 1,500 mg oral Curcuma longa per day or 240 mg simethicone per day. The patients assessed their symptoms using the dyspepsia Global Overall Symptom scale at baseline, week 2, and week 4. After stopping medication for 2 weeks, the patients assessed recurrent symptoms and day of recurrence by themselves at the end of week 6. Results: In total, 78 patients underwent randomization (27 in 750 mg Curcuma longa, 26 in 1500 mg Curcuma longa, and 25 in simethicone groups). After 2 weeks, there were no significant differences in all mean changes of symptoms scores (95%CI) of postprandial distress syndrome [-4.1 (-4.5, -2.6) vs -4.3 (-5.2, -3.3) vs -4.2 (-4.8, -3.5), P=0.954]. Over a period of 4 weeks, the reduction in mean scores was greater among participants receiving simethicone (although not statistically significant) compared with two intervention groups [-4.6 (-5.7, -3.6) vs -5.4 (-6.6, -4.1) vs -6.2 (-7.2, -5.2), P=0.122]. The rate of recurrence was significantly lower in simethicone than the two Curcuma longa groups (42.9 vs 45.5 vs 13.6%, P=0.047). There was no serious adverse event reported in all three groups. Conclusions: Curcuma longa had a similar effect on treatment outcomes to simethicone after 2 and 4 weeks, but the recurrence rate of symptoms was significantly higher without serious adverse events. Registration: Registered with the Thai Clinical Trials Registry on 31 January 2018; TCTR20180131001.

Curcuma longa Linn versus omeprazole in treatment of functional dyspepsia: A randomized, double‐blind, placebo‐controlled trial

“…34 Curcumin produced no serious adverse events, indicating it is safe. Our findings were similar to the findings of Sirijarugul and Pongchaidecha, 30 Sawangroj et al, 32 and Khonche et al 35 The current study was strengthened by the prospective design and randomized, double-blind, placebo-controlled trial study. This study provided evidence of six important aspects of dyspepsia treatment.…”

“…Most recent study from Panahi et al 27 showed that combination of famotidine and curcumin at , Omeprazole; , Curcumin; , Placebo. Pongchaidecha, 30 domperidone in the study by Nouvenne et al, 31 simethicone in the study by Sawangroj et al, 32 and famotidine in the study by Panahi et al 27 In our study, the omeprazole group showed efficacy in relieving pain symptoms and increasing satisfaction levels more than that of the placebo group. Surprisingly, omeprazole could not demonstrate improved non-pain symptoms compared with placebo.…”

A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders

“…All studies (Abbas et al, 2017; Alt et al, 2017; Asif et al, 2015; Banerjee et al, 2021; Bommelaer et al, 2020; Brinkhaus et al, 2005; Bundy et al, 2004; Hanai et al, 2006; Kedia et al, 2017; Khonche et al, 2016; Koosirirat et al, 2010; Kositchaiwat et al, 1993; Lang et al, 2015; Lauche et al, 2016; Lopresti et al, 2021; Masoodi et al, 2018; Panahi et al, 2021; Portincasa et al, 2016; Sadeghi et al, 2019; Sawangroj et al, 2019; Singla et al, 2014; Sirijarugul, 2007; Sugimoto et al, 2020; Thamlikitkul et al, 1989; Van Dau et al, 1998; Yongwatana et al, 2022) were published between 1989 and 2021 and were conducted in Asia ( n = 13) (Asif et al, 2015; Banerjee et al, 2021; Hanai et al, 2006; Kedia et al, 2017; Koosirirat et al, 2010; Kositchaiwat et al, 1993; Sawangroj et al, 2019; Singla et al, 2014; Sirijarugul, 2007; Sugimoto et al, 2020; Thamlikitkul et al, 1989; Van Dau et al, 1998; Yongwatana et al, 2022), Europe ( n = 6) (Alt et al, 2017; Bommelaer et al, 2020; Brinkhaus et al, 2005; Bundy et al, 2004; Lauche et al, 2016; Portincasa et al, 2016), the Middle East ( n = 5) (Abbas et al, 2017; Khonche et al, 2016; Masoodi et al, 2018; Panahi et al, 2021; Sadeghi et al, 2019), and Australia ( n = 1) (Lopresti et al, 2021), with one multi‐country study (i.e., Israel, Hong Kong, and Cyprus) (Lang et al, 2015). Twenty‐five studies were randomized controlled trials (RCTs) (Abbas et al, 2017; Alt et al,…”

Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials

“…Turmeric-based juice decreased plasma levels of p -cresyl sulfate (pCS), which is an important factor in the proper functioning of gut microbiota . Another study on postprandial distress syndrome associated with dyspepsia reported that treatment with C. longa capsules delayed the occurrence of functional dyspepsia, but also yielded a high recurrence rate . Other studies have evaluated the potential of turmeric in treating abdominal bloating associated with small bowel dysbiosis and irritable bowel syndrome.…”

“…434 Another study on postprandial distress syndrome associated with dyspepsia reported that treatment with C. longa capsules delayed the occurrence of functional dyspepsia, but also yielded a high recurrence rate. 435 Other studies have evaluated the potential of turmeric in treating abdominal bloating associated with small bowel dysbiosis and irritable bowel syndrome. These studies found that turmeric tablets were effective in relieving abdominal pain and discomfort.…”